Use of bone turnover markers in postmenopausal osteoporosis

R Eastell, P Szulc - The lancet Diabetes & endocrinology, 2017 - thelancet.com
Bone turnover comprises two processes: the removal of old bone (resorption) and the laying
down of new bone (formation). N-terminal propeptide of type I procollagen (PINP) and C …

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

S Vasikaran, R Eastell, O Bruyère, AJ Foldes… - Osteoporosis …, 2011 - Springer
Abstract Summary The International Osteoporosis Foundation (IOF) and the International
Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker …

Observations following discontinuation of long-term denosumab therapy

MR McClung, RB Wagman, PD Miller, A Wang… - Osteoporosis …, 2017 - Springer
Stop** denosumab after 8 years of continued treatment was associated with bone loss
during a 1-year observation study in patients who were not prescribed osteoporosis …

International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis

S Vasikaran, C Cooper, R Eastell… - Clinical Chemistry and …, 2011 - degruyter.com
Abstract The International Osteoporosis Foundation (IOF) and the International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC) Working Group on Bone Marker …

Bone turnover markers: use in osteoporosis

K Naylor, R Eastell - Nature Reviews Rheumatology, 2012 - nature.com
Biochemical markers of bone turnover (bone turnover markers, BTMs) can be used to study
changes in bone remodelling in osteoporosis. Investigators and clinicians should be aware …

Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis

M Lorentzon, J Branco, ML Brandi, O Bruyère… - Advances in …, 2019 - Springer
Introduction Increased biochemical bone turnover markers (BTMs) measured in serum are
associated with bone loss, increased fracture risk and poor treatment adherence, but their …

[HTML][HTML] Circulating microRNAs as novel biomarkers for bone diseases–complex signatures for multifactorial diseases?

M Hackl, U Heilmeier, S Weilner, J Grillari - Molecular and cellular …, 2016 - Elsevier
Biomarkers are essential tools in clinical research and practice. Useful biomarkers must
combine good measurability, validated association with biological processes or outcomes …

A meta-analysis of reference markers of bone turnover for prediction of fracture

H Johansson, A Odén, JA Kanis, EV McCloskey… - Calcified tissue …, 2014 - Springer
The aim of this report was to summarize the clinical performance of two reference bone
turnover markers (BTMs) in the prediction of fracture risk. We used an updated systematic …

[HTML][HTML] Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and …

J Burch, S Rice, H Yang, A Neilson… - Health technology …, 2014 - pmc.ncbi.nlm.nih.gov
BACKGROUND There is currently no standard practice for the monitoring of patients
receiving treatment for osteoporosis. Repeated dual-energy X-ray absorptiometry (DXA) is …

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

D Bauer, J Krege, N Lane, E Leary, C Libanati… - Osteoporosis …, 2012 - Springer
This position paper reviews how the National Bone Health Alliance (NBHA) will execute a
project to help assure health professionals of the clinical utility of bone turnover markers; the …